Key result
Among 62 patients with DLBCL, 17.7% developed VTE, but specific extracellular vesicle profiles were not significantly associated with the risk of VTE or overall survival.
Why the study?
Aggressive lymphomas carry a high VTE risk and extracellular vesicles (EVs) have emerged as potential biomarkers, but their profile and association with VTE in DLBCL remained to be determined.
Does the extracellular vesicle profile predict the risk of venous thromboembolism or overall survival in patients with diffuse large B-cell lymphoma?
Cohort (n=62)
Does the extracellular vesicle profile predict the risk of venous thromboembolism or overall survival in patients with diffuse large B-cell lymphoma?
Extracellular vesicle profiles are altered in DLBCL patients compared to healthy controls but do not significantly predict the risk of venous thromboembolism or overall survival.
EV profiles should not guide VTE risk assessment or prognosis in DLBCL; leaves open investigation of EVs in other outcomes or lymphoma subtypes.
Thrombosis is a common complication in cancer patients, with a substantial impact on morbidity and mortality. Diffuse large B-cell lymphoma (DLBCL) and other aggressive lymphomas carry a high venous thromboembolism (VTE) risk. Extracellular vesicles (EVs) have gained attention in recent research as a new potential biomarker for VTE development. To determine the profile and association of EVs with VTE in patients with DLBCL, we conducted a prospective cohort study on 62 patients diagnosed with DLBCL. A total of 11 patients (17.7%) developed VTE. The concentrations of platelet-derived EVs (PEVs), E-selectin+ EVs, P-selectin+ EVs, tissue factor (TF)-positive/CD20+ EVs, TF-/CD19+ EVs, TF-/CD45+ EVs, and TF-/CD20+ EVs were significantly higher in DLBCL patients compared to healthy controls. In contrast, the concentration of TF- PEVs was significantly lower in DLBCL patients compared to healthy controls. No statistically significant differences were observed in the concentrations of the EV profiles among the DLBCL patients with and without VTE. Using Cox regression analysis, we found that none of the observed EV populations demonstrated an association with overall survival (OS). In conclusion, patients with DLBCL have elevated concentrations of distinct EV populations-in particular, PEVs, E-selectin EVs, P-selectin EVs, TF+/CD20+ EVs, and TF- DLBCL/B-cell EVs (CD19, CD20, CD45)-compared to healthy controls. DLBCL patients exhibit a specific EV profile, which is not significantly related to the risk of VTE and OS outcomes. Our data provide an intriguing insight into EV profiles in patients with DLBCL. Additional research is needed to elucidate these findings further.
No takes yet. Share an insight, caveat, or question.
Otašević et al. (2025) conducted a cohort in Diffuse large B-cell lymphoma (DLBCL) (n=62). Extracellular vesicles (EVs) profile vs. Healthy controls / DLBCL patients without VTE was evaluated on Venous thromboembolism (VTE). Among 62 patients with DLBCL, 17.7% developed VTE, but specific extracellular vesicle profiles were not significantly associated with the risk of VTE or overall survival.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: